Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A inflammatory syndrome in adults infected by the SARS-CoV-2 with severe illness requiring hospitalization in a person aged ≥21 years; a positive test result for current or previous SARS-CoV-2 infection (nucleic acid, antigen, or antibody) during admission or in the previous 12 weeks; severe dysfunction of one or more extrapulmonary organ systems (e.g., hypotension or shock, cardiac dysfunction, arterial or venous thrombosis or thromboembolism, or acute liver injury); laboratory evidence of severe inflammation (e.g., elevated CRP, ferritin, D-dimer, or interleukin-6); and absence of severe respiratory illness (to exclude patients in which inflammation and organ dysfunction might be attributable simply to tissue hypoxia).
Data assembled from 1 of 12 sources · Last updated Sep 20, 2026, 3:14 PM UTC
Common questions about COVID-19–associated multisystem inflammatory syndrome in adults
AI-curated news mentioning COVID-19–associated multisystem inflammatory syndrome in adults
Updated Feb 27, 2026
A study published in PubMed analyzes serum metabolomic signatures in children with SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C). This research provides insights into the metabolic changes associated with these conditions, potentially guiding future therapeutic strategies.
Nearly 100 biotech companies went public in 2021, driven by pandemic investments, but many struggle to deliver results. Invivyd raised $336 million in a Series C round for its COVID-19 candidate ADG20, while Verve focuses on gene editing for cardiovascular diseases.
The CDC reports on the effectiveness of COVID-19 vaccines in children aged 9 months to 17 years, providing critical data for public health policy. This analysis covers the period from August 29, 2024, to September 2, 2025.
The CDC has launched a Nursing Home Data Dashboard featuring a COVID-19 module that tracks the impact on residents and staff in long-term care facilities. This initiative aims to enhance transparency and inform policy decisions regarding nursing home safety.
The FDA has issued Emergency Use Authorizations (EUA) for certain medical devices related to COVID-19, as mandated by the Federal Food, Drug, and Cosmetic Act. This announcement includes the requirement for the FDA to publish notices of each authorization in the Federal Register.